Back to the drawing board: Re-thinking the role of GLI1 in pancreatic carcinogenesis

Tara L. Hogenson; Matthias Lauth; Marina Pasca diMagliano; Martin E. Fernandez-Zapico

doi:10.12688/f1000research.5324.1

Back to the drawing board: Re-thinking the role of GLI1 in pancreatic carcinogenesis

Tara L. Hogenson, Matthias Lauth, Marina Pasca diMagliano, Martin E. Fernandez-Zapico

Oncology

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

Aberrant activation of the transcription factor GLI1, a central effector of the Hedgehog (HH) pathway, is associated with several malignancies, including pancreatic ductal adenocarcinoma (PDAC), one of most deadly human cancers. GLI1 has been described as an oncogene in PDAC, making it a promising target for drug therapy. Surprisingly, clinical trials targeting HH/GLI1 axis in advanced PDAC were unsuccessful, leaving investigators questioning the mechanism behind these failures. Recent evidence suggests the loss of GLI1 in the later stages of PDAC may actually accelerate disease. This indicates GLI1 may play a dual role in PDAC, acting as an oncogene in the early stages of disease and a tumor-suppressor in the late stages.

Original language	English (US)
Pages (from-to)	238
Number of pages	1
Journal	F1000Research
Volume	3
DOIs	https://doi.org/10.12688/f1000research.5324.1
State	Published - 2016

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)
Immunology and Microbiology(all)
Pharmacology, Toxicology and Pharmaceutics(all)

Access to Document

10.12688/f1000research.5324.1

Cite this

@article{b6b7679bf50045cc9e48a0b317887d12,

title = "Back to the drawing board: Re-thinking the role of GLI1 in pancreatic carcinogenesis",

abstract = "Aberrant activation of the transcription factor GLI1, a central effector of the Hedgehog (HH) pathway, is associated with several malignancies, including pancreatic ductal adenocarcinoma (PDAC), one of most deadly human cancers. GLI1 has been described as an oncogene in PDAC, making it a promising target for drug therapy. Surprisingly, clinical trials targeting HH/GLI1 axis in advanced PDAC were unsuccessful, leaving investigators questioning the mechanism behind these failures. Recent evidence suggests the loss of GLI1 in the later stages of PDAC may actually accelerate disease. This indicates GLI1 may play a dual role in PDAC, acting as an oncogene in the early stages of disease and a tumor-suppressor in the late stages.",

author = "Hogenson, {Tara L.} and Matthias Lauth and diMagliano, {Marina Pasca} and Fernandez-Zapico, {Martin E.}",

note = "Funding Information: This work was supported by National Institutes of Health Grant CA136526, Division of Oncology Research (Mayo Clinic), Mayo Clinic Pancreatic SPORE P50 Grant CA102701 and Mayo Clinic Center for Cell Signaling in Gastroenterology Grant P30 DK84567 (to M.E.F.-Z.). Publisher Copyright: {\textcopyright} 2016 Hogenson TL et al.",

year = "2016",

doi = "10.12688/f1000research.5324.1",

language = "English (US)",

volume = "3",

pages = "238",

journal = "F1000Research",

issn = "2046-1402",

publisher = "F1000 Research Ltd.",

}

TY - JOUR

T1 - Back to the drawing board

T2 - Re-thinking the role of GLI1 in pancreatic carcinogenesis

AU - Hogenson, Tara L.

AU - Lauth, Matthias

AU - diMagliano, Marina Pasca

AU - Fernandez-Zapico, Martin E.

N1 - Funding Information: This work was supported by National Institutes of Health Grant CA136526, Division of Oncology Research (Mayo Clinic), Mayo Clinic Pancreatic SPORE P50 Grant CA102701 and Mayo Clinic Center for Cell Signaling in Gastroenterology Grant P30 DK84567 (to M.E.F.-Z.). Publisher Copyright: © 2016 Hogenson TL et al.

PY - 2016

Y1 - 2016

N2 - Aberrant activation of the transcription factor GLI1, a central effector of the Hedgehog (HH) pathway, is associated with several malignancies, including pancreatic ductal adenocarcinoma (PDAC), one of most deadly human cancers. GLI1 has been described as an oncogene in PDAC, making it a promising target for drug therapy. Surprisingly, clinical trials targeting HH/GLI1 axis in advanced PDAC were unsuccessful, leaving investigators questioning the mechanism behind these failures. Recent evidence suggests the loss of GLI1 in the later stages of PDAC may actually accelerate disease. This indicates GLI1 may play a dual role in PDAC, acting as an oncogene in the early stages of disease and a tumor-suppressor in the late stages.

AB - Aberrant activation of the transcription factor GLI1, a central effector of the Hedgehog (HH) pathway, is associated with several malignancies, including pancreatic ductal adenocarcinoma (PDAC), one of most deadly human cancers. GLI1 has been described as an oncogene in PDAC, making it a promising target for drug therapy. Surprisingly, clinical trials targeting HH/GLI1 axis in advanced PDAC were unsuccessful, leaving investigators questioning the mechanism behind these failures. Recent evidence suggests the loss of GLI1 in the later stages of PDAC may actually accelerate disease. This indicates GLI1 may play a dual role in PDAC, acting as an oncogene in the early stages of disease and a tumor-suppressor in the late stages.

UR - http://www.scopus.com/inward/record.url?scp=85010919229&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010919229&partnerID=8YFLogxK

U2 - 10.12688/f1000research.5324.1

DO - 10.12688/f1000research.5324.1

M3 - Review article

AN - SCOPUS:85010919229

SN - 2046-1402

VL - 3

SP - 238

JO - F1000Research

JF - F1000Research

ER -

Back to the drawing board: Re-thinking the role of GLI1 in pancreatic carcinogenesis

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this